Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES, could replicate in cancer cells, and causes selective lysis of cancer cells. We further constructed OBP-405 ('Telomelysin-RGD') that contains an RGD motif in the HI loop of the fiber knob. We examined whether OBP-405 could be effective in overcoming the limitations of OBP-301, specifically their inefficient infection into cells lacking the primary receptor, the coxsackievirus and adenovirus receptor (CAR). By flow cytometric analysis, H1299 (lung) and SW620 (colorectal) tumor cells showed high levels of CAR expression, whereas LN444 (glioblastoma), LNZ308 (glioblastoma), and H1299-R5 (lung) tumor cells were negative for CAR expression. A quantitative realtime PCR analysis demonstrated that fiber-modified OBP-405 infected more efficiently than OBP-301, although the intracellular replication rate of both viruses was consistent. The comparative antitumor effect of fibermodified OBP-405 and unmodified OBP-301 for human cancer cells was evaluated in vitro by XTT assay as well as in vivo by using athymic mice carrying xenografts. OBP-405 had a profound oncolytic effect on human cancer cell lines compared to OBP-301, in particular on cells with low CAR expression. Intratumoral injection of 10 7 plaque-forming units of OBP-405 into CAR-negative H1299-R5 lung tumor xenografts in nu/nu mice resulted in a significant inhibition of tumor growth and long-term survival in all treated mice. Moreover, selective replication of OBP-405 in the distant, uninjected H1299-R5 tumors was demonstrated. Our results suggest that fiber-modified replication-competent adenovirus OBP-405 exhibits a broad target range by increasing infection efficiency, an outcome that has important implications for the treatment of human cancers.
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Introduction
The optimal treatment for human cancer requires an improvement of therapeutic ratio to increase cytotoxic efficacy on the tumor cells and decrease that on the normal cells. This may not be an easy task because most of normal cells surrounding tumors are sensitive to the cytotoxic treatment. Thus, to establish reliable therapeutic strategies for human cancer, it is important to seek the genetic and epigenetic targets present only in cancer cells. The emerging fields of functional genomics and functional proteomics provide an expanding repertoire of clinically applicable targeted therapeutics (Kohn et al., 2004) . Telomerase is a ribonucleoprotein complex responsible for the addition of TTAGGG repeats to the telomeric ends of chromosomes (Greider and Blackburn, 1985; Collins and Mitchell, 2002) , and contains the enzymatic subunit human telomerase reverse transcriptase (hTERT) (Nakamura et al., 1997) . The hTERT proximal promoter can be used as a molecular switch for the selective expression of target genes in tumor cells (Koga et al., 2000; Komata et al., 2001; Gu et al., 2000 Gu et al., , 2002 , since almost all advanced human cancer cells express telomerase and most normal cells do not (Kim et al., 1994; Shay and Wright, 1996) . Genetically modified adenoviruses have emerged as a new biological anticancer agent (McCormick, 2001; Fang and Roth, 2003) . We previously constructed an adenovirus vector (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site (IRES), and showed that OBP-301 induced selective E1A and E1B expression in human cancer cells, but not in normal cells . Therefore, OBP-301 can replicate and lyse only cancer cells, but not normal cells. In addition, OBP-301 will infect neighboring cancer cells, and induce oncolysis throughout the whole tumor mass in vivo.
Infection efficiency of the presently available adenoviral agent, which is derived from human adenovirus serotype 5, varies widely depending on the expression of Coxsackie-adenovirus receptor (CAR) (Wickham et al., 1993) . The initial step of adenovirus infection involves at least two sequential steps. The first step is the attachment of the virus to the cell surface through binding of the knob domain of the fiber to CAR (Bergelson et al., 1997) . Following attachment, the viral internalization into the cells occurs by the interaction of RGD (ArgGly-Asp) motifs of penton base with integrin receptors, avb3 and avb5, expressed on most cell types (Wickham et al., 1993) . Therefore, the interaction of the fiber knob with CAR on the cell is the key mediator by which adenoviral agents enter the cells. Modification of fiber protein is an attractive strategy for overcoming the limitations imposed by the CAR dependence of adenovirus infection (Wickham et al., 1997; Dmitriev et al., 1998; Krasnykh et al., 1998; Mizuguchi et al., 2001) .
We modified the fiber of OBP-301 to contain RGD peptide, which binds with high affinity to integrins (avb3 and avb5) on the cell surface, on the HI loop of the fiber protein. The resultant adenovirus, termed OBP-405 or 'Telomelysin-RGD', mediated not only CAR-dependent virus entry but also CAR-independent, RGD-integrin (avb3 and avb5)-dependent virus entry. We explored whether OBP-405 containing RGD peptide on the fiber knob had more oncolytic efficacy on several types of human cancer cells (CAR-positive or -negative), as compared with OBP-301 containing wild-type fiber in vitro and in vivo.
Results

Expression of CAR and integrins in human cancer and normal cells
To investigate the antitumor effect of the fiber-modified OBP-405, we used several human cell lines. We first examined the expression levels of CAR and av integrin family, avb3 and avb5, on each cell surface by flow cytometric analysis (Figure 1 ). Apparent amounts of CAR expression were detected on H1299 and SW620 cells, whereas LN444, LNZ308, and H1299-R5 cells expressed extremely low levels of CAR. The normal human lung fibroblast (NHLF) cell also exhibited detectable CAR expression. In contrast to CAR, avb3 and avb5 integrins were readily expressed in all cell lines.
Increased infection efficiency and selective replication of OBP-405
To assess whether incorporation of an RGD motif into the HI loop of the fiber knob domain would enhance its infectivity, CAR-positive parental H1299, CAR-negative LN444, and NHLF (normal cell) were infected with OBP-301 or OBP-405 at an multiplicity of infection (MOI) of 1. Quantitative real-time PCR analysis with DNA extracted 2 h after infection demonstrated that the amount of E1A DNA after OBP-405 infection was higher than that after OBP-301 infection in two human cancer cell lines, whereas infectivity of both viruses was almost similar in NHLF (Figure 2a) . These results suggest that RGD-modified OBP-405 showed increased infectivity to neoplastic cells regardless of the levels of CAR expression, although the infectivity enhancement was greater in CAR-negative cancer cells.
We next examined the replication ability of OBP-301 and OBP-405 in different cell lines by measuring the relative amounts of E1A DNA. H1299, LN444, and NHLF cells were harvested at the indicated time points over 72 h after infection with OBP-301 or OBP-405, and subjected to quantitative real-time PCR analysis. The ratios were normalized by dividing the value of cells obtained 2 h after viral infection. As shown in Figure 2b , both OBP-301 and OBP-405 replicated 5-6 logs by 72 h after infection; their replication, however, were attenuated up to 3 logs in normal NHLF cells.
Enhanced viral spread of OBP-405 in human cancer cells
To examine whether increased infectivity of OBP-405 could facilitate viral spread, H1299, LN444, and NHLF cells cultured in chamber slides were infected either with OBP-301 or OBP-405 at an MOI of 1, and then immunohistochemically stained for viral hexon at 24 and 48 h of postinfection. Viral hexon was detectable in H1299 cells infected with OBP-301 and OBP-405 in a time-dependent manner, although the amount of positive cells after OBP-405 infection was higher than that after OBP-301 infection (Figure 3a) . In contrast, viral hexon was only present in CAR-negative LN444 cells infected with OBP-405, but not in OBP-301-infected LN444 cells (Figure 3b To test whether the increased infectivity and replication of OBP-405 translated to improved oncolysis, we compared the cytopathic effect of OBP-405 with that of OBP-301 on various human cell lines in vitro (Figure 4 ). Both OBP-301 and OBP-405 killed CARpositive H1299 and SW620 human cancer cells in a dose-dependent manner; OBP-405 at an MOI of 0.1, however, killed these cells as efficiently as OBP-301 at an MOI of 1, suggesting that OBP-405 showed approximately 10-fold more profound tumor cell killing compared with OBP-301. In contrast, only OBP-405 was lytic in CAR-negative LN444, LNZ308, and H1299-R5 cells, likely due to the higher infectivity of OBP-405 in these cell lines. Most of these cells were dead within 5 days after OBP-405 infection, whereas OBP-301-infected cells were still intact at 5 days postinfection (Figure 4b ). Neither OBP-301 nor OBP-405 exhibited cytopathic effect on NHLF cells.
Enhanced oncolysis of CAR-negative tumor xenografts by OBP-405
We next examined whether OBP-405 cause enhanced oncolysis and spread in vivo. Subcutaneous H1299-R5 tumor xenografts with a diameter of 5-6 mm received three daily courses of intratumoral injection of 1 Â 10 7 plaque-forming units (PFU) of OBP-301, OBP-405 or replication-deficient control adenovirus (dl312), or PBS (mock). As shown in Figure 5 , administration of OBP-405 resulted in significant growth suppression compared to mock-or dl312-treated tumors 34 days after virus injection (Po0.01). In addition, one of the six mice treated with OBP-405 showed the complete eradication of the established H1299-R5 tumor. We previously reported that intratumral injection of OBP-301 significantly inhibited the growth of H1299 tumor xenografts; a modest, insignificant growth inhibition, however, occurred with administration of OBP-301 on H1299-R5 tumors. Treatment with replication-deficient dl312 had no apparent effect on the growth of H1299-R5 tumors.
Targeting replication of OBP-405 in tumor tissues in vivo
To evaluate selective replication of OBP-301 and OBP-405 in vivo, we examined mouse tissues including implanted tumors for the presence of viral DNA and protein by quantitative real-time PCR and immunohistochemistry, respectively, following intratumoral viral Figure 1 Flow cytometric analysis of CAR and integrin (avb3 and avb5) expression in human cancer and normal cell lines. Cells were incubated with anti-CAR (RmcB), anti-avb3 integrin (LM609), and anti-avb5 integrin (P1F6) monoclonal antibodies, followed by detection with FITC-labeled goat anti-mouse IgG secondary antibody. An isotype-matched normal mouse IgG1 conjugated to FITC was used as a control in all experiments (solid line) RGD-modified telomerase-specific oncolytic adenovirus M Taki et al injection. Mice with established subcutaneous H1299-R5 tumors received three daily courses of intratumoral injection of 1 Â 10 7 PFU of OBP-301 or OBP-405, or PBS (mock), and killed 7 days after treatment. E1A DNA was not detected in any normal tissues examined (liver, kidney, pancreas, and spleen), however, it was apparently detected in tumors ( Figure 6a ). Tumors from mice treated with OBP-405 contained 100-fold more E1A DNA than tumors from OBP-301-treated mice ( Figure 6a ). Immunohistochemical staining of adenoviral hexon protein revealed that OBP-405 mediated viral spread throughout the tumor tissues that was less evident in OBP-301-treated animals ( Figure 6b ). In other normal organs, adenoviral hexon protein was absent (data not shown).
To directly address whether OBP-405 is not toxic, we measured levels of liver enzymes as an indicator of hepatocellular damages 7 days after intratumoral injection of 1 Â 10 7 PFU of viruses. As shown in Table 1 , no significant elevation of liver enzymes was observed in mice intratumorally injected with OBP-301 or OBP-405. In addition, histopathological analysis of liver sections demonstrated that there were no apoptotic hapatocytes or other histological signs of hapatocellular damages in mice treated with either OBP-301 or OBP-405 (data not shown).
Viral spread of OBP-405 in distant tumor tissues after intratumoral injection
We finally tested whether intratumoral injection of OBP-405 could mediate a therapeutic benefit on distant, uninjected H1299-R5 tumors in a dual tumor model. H1299-R5 tumors were established in the flanks at both left and right sides of nu/nu mice and viral replication in the left tumors was assessed after intratumoral inoculation of 1 Â 10 7 PFU of either OBP-301 or OBP-405 into tumors in the right flank. Quantitative real-time PCR analysis on postinfection day 14 demonstrated that OBP-405 caused approximately 100-fold more efficient replication than OBP-301 in H1299-R5 tumors injected with viruses, whereas only OBP-405 replicated on distant, uninjected H1299-R5 tumors (Figure 7a) .
At four weeks after viral injection, OBP-301 also replicated in uninjected H1299-R5 tumors; OBP-405, however, resulted in an approximately 100-fold more replication at uninjected sites (Figure 7b ). In contrast, RGD-modified telomerase-specific oncolytic adenovirus M Taki et al H1299-R5 tumor treated with OBP-405 had completely disappeared, and the level of E1A copy number of OBP-301 was almost consistent with that at 14 day postinfection. These results suggest that OBP-405 could more efficiently replicate in both injected and uninjected tumors, when CAR-negative H1299-R tumors were treated. Notably, no E1A DNA could be detected in the blood of mice treated with OBP-301 or OBP-405, indicating that viral replication in tumors dose not correlate with the level of viruses in the blood circulation (Figure 7a and b) . Moreover, we histologically confirmed a profound replication of OBP-405 in untreated H1299-R5 tumors. As shown in Figure 7c , immunohistochemical analysis for the detection of adenoviral hexon demonstrated that the percentage of positive-staining cells was apparently higher in uninjected tumors of OBP-405-treated mice than those of OBP-301-treated mice. Hematoxylin/eosin analysis revealed apparent tumor cell death at the central portions of the tumors; morphological changes, however, that are associated with the apoptotic phenotype such as nuclear fragmentation and chromatin condensation were not evident (data not shown), suggesting that oncolysis by viral replication might be nonapoptotic cell death.
Discussion
Viral replication generally results in tissue destruction. Oncolytic viruses have been developed as an anticancer agent, because controlled replication in the tumors causes selective killing of tumor cells and minimizes the undesired effects on normal cells (Kirn et al., 2001) . Amplified viruses can infect adjacent tumor cells as well as reach distant metastatic tumors with the blood circulation. Therefore, oncolytic viruses can amplify the administered dose as a result of in vivo viral replication. This might be one of the potential advantages of oncolytic viruses compared with conventional cancer therapies. We previously reported that hTERT promoter-specific replication-competent adenovirus OBP-301 could replicate and eventually lyse the telomeraseexpressing tumors cells, leading to the viral spread to adjacent cells . OBP-301 could infect both normal and tumor cells, but the virus would only replicate in those cells that have robust telomerase activity. OBP-301 induced oncolysis in a variety of human cancer cell lines; tumors that lost CAR expression, however, might be refractory to infection with OBP-301, because subgroup C adenoviruses, including serotypes 2 and 5, rely on CAR as the primary binding , 1997) . In fact, CAR deficiency in primary tumors has been reported Li et al., 1999) . Here, we demonstrate that the modification of the adenovirus fiber knob by the addition of an RGD-containing peptide in the HI loop increased its infectious efficiency and enabled the virus to kill CAR-negative tumor cells. The fiber-modified new oncolytic adenovirus OBP-405 was more effective to inhibit the growth of CARnegative tumors in vivo, comprised of OBP-301. A wide spectrum of CAR levels exists among many types of human cancer lines (Figure 1 ), although the regulation as well as the function of this transmembrane protein are poorly understood. If expression of CAR on target cells could be increased, this could potentially yield improved efficacy of adenovirus-based therapies. We previously established H1299-R5 human lung cancer cell line refractory to adenovirus infection by five-time repeated infections (Tango et al., 2004) . The observation that CAR expression markedly diminished as the cells are repeatedly infected with adenovirus suggests that the levels of CAR expression could be altered. Indeed, It has been reported that the chemotherapeutic agents are effective in increasing CAR expression (Hemminki et al., 2003) ; in our preliminary experiments, however, CAR expression could not be modified in H1299-R5 cells by any chemotherapeutic agents tested, including the EGF receptor-tyrosine kinase inhibitor ZD1839 (Gefitinib, 'Iressa') (data not shown). Therefore, it seems to be difficult to consistently upregulate CAR expression in various types of human cancer cells.
A variety of strategies have been devised to increase adenovirus infection to cells with low or absent CAR. For our study, we have chosen to alter the tropism of oncolytic virus by the modification of the fiber. Making the fiber-modified oncolytic adenovirus, we supposed that the virus could infect not only by CAR-dependent entry but also by CAR-independent, RGD-integrin (avb3 and avb5)-dependent entry. As expected, OBP-405 was taken up efficiently by both CAR-positive and CAR-negative human cancer cells; the infectivity of OBP-405 was 10-and 1000-fold higher in CAR-positive and CAR-negative human cancer cell lines, respectively, than that of OBP-301 (Figure 2a) . In contrast, the replication yields of OBP-301 and OBP-405 were persistent in both cell lines (Figure 2b) , indicating that the tropism modification is not anticipated to alter fundamental aspects of the viral replication cycle. The increased initial virus entry into the cells results in earlier detection (data not shown) and augmented yields of OBP-405 compared with unmodified OBP-301 (Figure 3) . Enhancing the infection efficiency of OBP-405 translated into increased oncolytic effects (Figure 4) . OBP-301 showed complete oncolysis at as low as 1 MOI in H299 and SW620 cells, suggesting that OBP-301 is sufficient to treat CAR-positive human cancer cells; OBP-301, however, could not kill CAR-negative cell lines at all. Notably, OBP-405 did effectively kill LN444, LNZ308, and H1299-R5 cells at an MOI of 1, indicating that the infection enhancement of OBP-405 contributed to its efficacy on CAR-negative cancer cells. Another important finding is that OBP-405 elicited no increased infectivity as well as cytopathic effect to normal cells despite of CAR expression (Figures 3 and 4) .
We also demonstrated the superior oncolytic effect of OBP-405 in the subcutaneous xenograft model of CARnegative H1299-R5 cells. Intratumoral injection of OBP-405 for three consecutive days resulted in the significant inhibition of H1299-R5 tumor growth ( Figure 5 ) and selective spread of viruses throughout the tumor tissues (Figure 6b ). Although the RGD fiber knob modification of selectively replicating adenoviruses, such as AdD24 containing the Rb-binding mutation in E1A (Lamfers et al., 2002) and the cyclooxygenase-2 (Cox-2) promoter-based adenovirus (Davydova et al., 2004) , has been previously reported to reduce tumor size in vivo, the major advantage of OBP-405 is the broad applicability for many types of human cancers because of the telomerase-specific hTERT promoter. In fact, many studies have reported that telomerase is present in nearly all immortal cell lines and B90% of human tumors but seldom in normal somatic cells (Kim et al., 1994; Shay and Wright, 1996) . In addition to the antitumor effect, when the tropism of the virus is modified, it has to be addressed whether a pattern of biodistribution could be affected. We observed that OBP-405 showed a tumorrestricted pattern of biodistribution in mice after intratumoral administration (Figure 6a ) and no hepatotoxicity despite of high levels of CAR and av integrin expression in the liver (Tomko et al., 1997; Fechner et al., 2000) (Table 1) . Viral replication and spread of OBP-405 could be detected at least for 4 weeks (Figure 7b ), whereas OBP-405 was negative in any normal specimen throughout the period (data not shown). A limitation of our biodistribution data is that the hTERT promoter is not expected to function in mice as it does in humans. Indeed, some studies have reported that mouse and rat tumors do not support efficient replication of human 
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Figure 5 Antitumor effects of intratumorally injected OBP-301 or OBP-405 against established flank H1299-R5 xenograft tumors in nu/nu mice. PBS and replication-deficient dl312 were used as a control. Six mice were used for each group. The tumor growth was expressed by the tumor mean volume 7s.e. Statistical significance (*) was defined as Po0.01 (Student's t-test) adenoviruses (Ginsberg et al., 1991; Prince et al., 1993) . However, as preliminary data, we confirmed that OBP-405 could infect and efficiently lyse murine adenocarcinoma cell line Colon-26 (data not shown). Therefore, OBP-405 is considered to be specific and safe within its therapeutic window.
To treat distant, metastatic tumors, an infusion of chemotherapeutic drugs by intravenous administration will need to distribute a sufficient quantity of agents to the tumor sites; oncolytic viruses, however, could replicate in the tumor, cause oncolysis, and then release virus particles that will reach to the distant metastatic lesions. Therefore, intratumoral administration that causes the release of newly formed virus from infected tumor cells might be theoretically suitable for oncolytic virus rather than systemic administration. OBP-405 cleared rapidly from the body after intravenous administration (data not shown). This is one of the reasons why we also used intratumoral injection of OBP-405 for the toxicity analysis. In fact, a phase I clinical study demonstrated PSA-specific oncolytic virus shedding in the blood after intraprostatic delivery (DeWeese et al., Table 1 Assessment of hepatotoxicity in nu/nu mice intratumorally injected with OBP-301 or OBP-405 Blood was obtained from H1299-R5 tumor-bearing mice 7 days after intratumoral injection of PBS or 1 Â 10 7 PFU of OBP-301 or OBP-405, and the levels of liver enzymes were analysed RGD-modified telomerase-specific oncolytic adenovirus M Taki et al 2001). These findings indicate that the intratumorally administered virus that reached the circulation could potentially replicate and lyse metastatic tumors. We observed evidence of OBP-405 replication in the distant, uninjected H1299-R5 tumors after its intratumoral administration into the contralateral tumors by quantification of virus DNA (Figure 7) . Moreover, OBP-405 continued to replicate in the distant tumors even after the injected tumors disappeared, although the presence of OBP-405 in the blood circulation could not be detected over time. One possible explanation for this result is that the amount of OBP-405 in the circulation might be quite small due to its short half-life (approximately 2 min) (Huard et al., 1995; Wood et al., 1999) , but sufficient to initiate replication once it reached the distant tumors.
In conclusion, we demonstrate that the fiber-modified telomerase-specific replication-selective adenovirus OBP-405 permits CAR-independent cell entry and effective destruction of tumors lacking the primary CAR. The feasibility of original OBP-301 (Telomelysin) for human cancer therapy will be confirmed in clinical trials in the near future; some CAR-negative tumors, however, may be refractory to OBP-301. Under such circumstances, OBP-405 is a powerful way of overcoming low infectivity and increasing antitumor activity. Our data may be consequential for the development of virotherapy for human cancers.
Materials and methods
Cells and culture conditions
The H1299 and H1299-R5 human non-small-cell lung cancer cell lines and the SW620 human colon cancer cell line were cultured in RPMI 1640 medium supplemented with 10% FCS. H1299-R5 is a subline of H1299 that are refractory to adenovirus infection due to the decreased CAR expression (Tango et al., 2004) . The human glioma cell lines LN444 and LNZ308 (kindly provided by Dr N Ishi, Hokkaido University, Hokkaido, Japan), and the transformed embryonic kidney cell line 293 were cultured in DMEM containing high glucose (4.5 g/l) and supplemented with 10% FCS. The normal human lung fibroblast cell line NHLF was purchased from TaKaRa Biomedicals (Kyoto, Japan) and cultured in the medium recommended by the manufacturer.
Recombinant adenoviruses
The recombinant replication-selective, tumor-specific adenovirus vector OBP-301 ('Telomelysin') was previously constructed and characterized Umeoka et al., 2004) . OBP-405 ('Telomelysin-RGD') that has mutant fiber containing the RGD peptide, CDCRGDCFC, in the HI loop of the fiber knob was created using the method developed by Mizuguchi et al. (2001) . OBP-301 and OBP-405 viruses were purified by CsCl 2 step gradient ultracentrifugation followed by CsCl 2 linear gradient ultracentrifugation. Determination of virus particle titer and infectious titer was accomplished spectrophotometrically by the method of Maizel et al. (1968) and by the method of Kanegae et al. (1994) , respectively.
Flow cytometry
The cells (2 Â 10 5 cells) were labeled with mouse monoclonal anti-CAR (RmcB; Upstate Biotechnology, NY, USA), antihuman integrin avb3 (LM609; Chemicon International, Temecula, CA, USA), or anti-human integrin avb5 (P1F6; Chemicon International, Temecula, CA, USA). Then, the cells were incubated with FITC-conjugated rabbit anti-mouse IgG second antibody (Zymed Laboratories, San Francisco, USA) and analysed by flow cytometry (FACScan, Becton Dickinson, Mountain View, CA, USA).
Quantitative real-time PCR assay DNA was extracted with QIAamp DNA Mini Kit (Qiagen Inc., Valencia, CA, USA), and quantitative real-time PCR assay for the E1A gene was performed using a LightCycler instrument (Roche Molecular Biochemicals, Indianapolis, IN, USA). The sequences of specific primers used for E1A were as follows: sense: 5 0 -CCT GTG TCT AGA GAA TGC AA-3 0 and antisense: 5 0 -ACA GCT CAA GTC CAA AGG TT-3 0 ). PCR amplification began with a 600-s denaturation step at 951C and then 40 cycles of denaturation at 951C for 10 s, annealing at 581C for 15 s, and extension at 721C for 8 s. Data analysis was performed using LightCycler Software (Roche Molecular Biochemicals). The ratios normalized by dividing the value of untreated cells were presented for each sample.
Viral spread assay
H1299, LN444, and NHLF were cultured in two-well chamber slides and infected with OBP-301 or OBP-405 at an MOI of 1. The slides were fixed with 4% paraformaldehyde 24 or 48 h after infection, blocked, incubated with FITC-labeled goat anti-hexon polyclonal antibody (25 mg/ml; Chemicon Inc., Temecula, CA, USA), and counterstained with DAPI (1 mg/ml; Molecular Probes, Eugene, OR, USA). The slides were photographed under the fluorescence microscopy and then analysed using the software (Viewfinder; Pixera, CA, USA).
Cell killing assay
Cells were plated at 100 000 cells/well on 12-well plates and infected either with OBP-301 or OBP-405 at an MOI of 0, 0.1, or 1 for 2 h. The medium with 10% FBS was then added following the removal of viruses. Coomassie brilliant blue staining was performed on day 5.
Cell viability assay
An XTT assay was performed to measure cell viability. Cells were plated on 96-well plates at 5 Â 10 3 /well, 24 h before infection and infected either with OBP-301 or OBP-405 at an MOI of 0, 0.1, or 1. Cell viability was determined at the indicated times by using a Cell Proliferation Kit II (Roche Molecular Biochemicals) according to the manufacturer's protocol.
In vivo human tumor model
Human lung cancer H1299-R5 cells (1 Â 10 7 cells/mouse) were subcutaneously injected into the flank of 5-6-week-old female BALB/c nu/nu mice and permitted to grow to approximately 5-6 mm in diameter. At that time, the mice were randomly assigned into four groups, and a 100 ml solution containing 1 Â 10 7 PFU of dl312, OBP-301, or OBP-405, or PBS was injected into the tumor on days 1, 2, and 3. Tumors were measured for perpendicular diameters every 3 or 4 days, and tumor volume was calculated using the following formula: tumor volume (mm 3 ) ¼ a Â b 2 Â 0.5, where a is the longest diameter, b is the shortest diameter, and 0.5 is a constant to calculate the volume of an ellipsoid. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Okayama University Graduate School of Medicine and Dentistry.
In vivo toxicity study
Mice bearing H299-R5 tumors received intratumoral injection of 1 Â 10 7 PFU of OBP-301 or OBP-405, or PBS. At 1 week after treatment, blood samples were obtained and the serum levels of total bilirubin (T-Bil), aspartate amino transferase (AST), alanine amino transferase (ALT), lactate dehydrogenase (LDH), gamma glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP) were determined by automated colorimetric assays to assess the hepatotoxicity.
In vivo viral replication OBP-301 or OBP-405 at 1 Â 10 7 PFU/100 ml, or PBS were intratumorally injected into H1299-R5-bearing mice. After 1 week, the tumors and organs were harvested and DNA was extracted from each tissue. To compare the viral replication in the tumor and other normal organs, quantitative real-time PCR for the E1A gene was performed with a LightCycler instrument. The tumors and organs were immediately embedded in Tissue Tek (Sakura, Tokyo, Japan), cut into 5 mm-thick sections, and assessed by immunofluorescence detection of the adenoviral hexon protein using a goat antihexon polyclonal antibody (Chemicon, Temecula, CA, USA). To assess the viral replication on distant, uninjected tumors, H1299-R5 cells (1 Â 10 7 cells/mouse) were injected subcutaneously into bilateral flanks of mice. At 2 weeks or 1 month after intratumoral inoculation of OBP-301 or OBP-405 at 1 Â 10 7 PFU/100 ml into tumors in the right flank, the bilateral tumors and blood were collected from mice and DNA was extracted. Quantitative real-time PCR as well as immunofluorescence staining for the hexon protein were performed.
Statistical analysis
Determinations of significant differences among groups were assessed by calculating the value of Student's t using the original data analysis.
Abbreviations hTERT, human telomerase reverse transcriptase; IRES, internal ribosome entry site; CAR, Coxsackie-adenovirus receptor; NHLF, normal human lung fibroblasts; MOI, multiplicity of infection; PFU, plaque-forming units.
